- Home
- REE vs ACTU Comparison
REE vs ACTU Comparison
Compare REE & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- ACTU
- Stock Information
- Founded
- REE 2011
- ACTU 2015
- Country
- REE Israel
- ACTU United States
- Employees
- REE N/A
- ACTU N/A
- Industry
- REE Auto Manufacturing
- ACTU
- Sector
- REE Consumer Discretionary
- ACTU
- Exchange
- REE Nasdaq
- ACTU NYSE
- Market Cap
- REE 153.8M
- ACTU 153.1M
- IPO Year
- REE N/A
- ACTU 2024
- Fundamental
- Price
- REE $7.25
- ACTU $8.98
- Analyst Decision
- REE Buy
- ACTU
- Analyst Count
- REE 4
- ACTU 0
- Target Price
- REE $9.25
- ACTU N/A
- AVG Volume (30 Days)
- REE 50.2K
- ACTU 59.7K
- Earning Date
- REE 11-29-2024
- ACTU 11-13-2024
- Dividend Yield
- REE N/A
- ACTU N/A
- EPS Growth
- REE N/A
- ACTU N/A
- EPS
- REE N/A
- ACTU N/A
- Revenue
- REE $825,000.00
- ACTU N/A
- Revenue This Year
- REE N/A
- ACTU N/A
- Revenue Next Year
- REE $50,620.25
- ACTU N/A
- P/E Ratio
- REE N/A
- ACTU N/A
- Revenue Growth
- REE N/A
- ACTU N/A
- 52 Week Low
- REE $2.91
- ACTU $5.51
- 52 Week High
- REE $8.79
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- REE 50.95
- ACTU N/A
- Support Level
- REE $6.16
- ACTU N/A
- Resistance Level
- REE $8.79
- ACTU N/A
- Average True Range (ATR)
- REE 0.62
- ACTU 0.00
- MACD
- REE -0.09
- ACTU 0.00
- Stochastic Oscillator
- REE 41.44
- ACTU 0.00
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.